Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease.
about
Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activationChronic unpredictable stress (CUS)-induced anxiety and related mood disorders in a zebrafish model: altered brain proteome profile implicates mitochondrial dysfunctionAbsence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathwaysUrsocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease.Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.Life-time expression of the proteins peroxiredoxin, beta-synuclein, PARK7/DJ-1, and stathmin in the primary visual and primary somatosensory cortices in rats.Association between AKT1 Gene Polymorphism rs2498794 and Smoking-Related Traits with reference to Cancer Susceptibility.Unveiling transient protein-protein interactions that modulate inhibition of alpha-synuclein aggregation by beta-synuclein, a pre-synaptic protein that co-localizes with alpha-synuclein.Chaperone and anti-chaperone: two-faced synuclein as stimulator of synaptic evolution.Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic modelsPlasma and White Blood Cells Show Different miRNA Expression Profiles in Parkinson's Disease.Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins.Beta-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with alpha-synuclein.PINK1 overexpression protects against C2-ceramide-induced CAD cell death through the PI3K/AKT pathway.PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies.Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein.Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment.4R-Cembranoid Improves Outcomes after 6-Hydroxydopamine Challenge in Both In vitro and In vivo Models of Parkinson's Disease.An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model.Characterization of three synuclein genes in Xenopus laevis.Beta-synuclein exhibits chaperone activity more efficiently than alpha-synuclein.Potential of mean force and molecular dynamics study on the transient interactions between α and β synuclein that drive inhibition of α-synuclein aggregation.Evidence of oxidative stress in the neocortex in incidental Lewy body disease.Strain-independent global effect of hippocampal proteins in mice trained in the Morris water maze.Gamma-synuclein binds to AKT and promotes cancer cell survival and proliferation.The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies.
P2860
Q28477043-291D8CF4-C880-4967-B596-B850E03277C7Q28488002-84AB0038-9B0A-4252-A991-26F9E12945CAQ33394700-5EBAE34B-792D-4F42-952C-87C9160D87FBQ33996828-FE907DF0-A4F5-4A10-8253-482EBBD7498BQ34146349-F1420809-4D86-4285-9844-DCA1B2D8468FQ34977478-329B4728-03B2-4D7F-88B5-F3F54BD4EFF4Q35000764-A477EAE6-377E-4787-9068-8D9423D5C4BEQ35146028-11EE8484-EABE-480B-A4C4-B36C55B8A7B7Q35763163-EE269598-BE67-46E5-A751-99C1CCC58126Q36174650-9B9412AD-43A1-42FC-B367-A6FF063BF4ECQ36642450-FAC12C42-01C9-4C6D-B28E-3C80E0176862Q37356319-EB07584D-C723-401E-9AA0-5926999B18CDQ38765914-238E2B1A-E126-4CC8-9AE2-3CF8B36BD345Q38822626-1AEDC7B4-19E8-432E-A089-A89D20429AA1Q39407567-23C21646-3DD4-47F8-9696-2AF4496781E0Q39418832-DCB13788-E54A-47FE-8671-E73EEF422088Q39800916-B83EB7E1-1DAA-4CFF-858C-0073F9BBEE8EQ40102845-E6CCDAF0-9785-49FD-8A16-91AB7DDBF857Q40155070-3E902848-B1A5-42E3-98DA-E917ECE1E0BAQ42148662-FB4D4054-F103-40C1-A3BA-3D92F4647A2EQ42241279-A448C4D4-28B7-40FC-BEE5-709161407645Q43865449-0CD087B8-9743-4529-8723-7EEC15ECCDDCQ44738578-A35B8367-B889-4D82-8655-F35DBC3C6EBDQ45097964-B5406B60-59C4-41F3-996E-B7F1155A77FFQ46464490-B54B5C29-F618-4079-9258-31BF7AF9E239Q46686665-E54D2C6B-C8D1-4E99-B04E-E834621925DAQ48622962-45BC74CF-61D6-41DE-94B2-F0C3A6D52B93Q51452297-EF52F654-45D0-4341-BF75-D18A50930A6CQ53313817-3284EF7A-F609-429B-A37F-C94036B77869
P2860
Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Beta-synuclein regulates Akt a ...... ection in Parkinson's disease.
@ast
Beta-synuclein regulates Akt a ...... ection in Parkinson's disease.
@en
Beta-synuclein regulates Akt a ...... ection in Parkinson's disease.
@nl
type
label
Beta-synuclein regulates Akt a ...... ection in Parkinson's disease.
@ast
Beta-synuclein regulates Akt a ...... ection in Parkinson's disease.
@en
Beta-synuclein regulates Akt a ...... ection in Parkinson's disease.
@nl
prefLabel
Beta-synuclein regulates Akt a ...... ection in Parkinson's disease.
@ast
Beta-synuclein regulates Akt a ...... ection in Parkinson's disease.
@en
Beta-synuclein regulates Akt a ...... ection in Parkinson's disease.
@nl
P2093
P2860
P356
P1476
Beta-synuclein regulates Akt a ...... ection in Parkinson's disease.
@en
P2093
Gilbert Ho
Leslie Crews
Makoto Hashimoto
Pazit Bar-On
Takato Takenouchi
P2860
P304
23622-23629
P356
10.1074/JBC.M313784200
P407
P577
2004-03-16T00:00:00Z